Covaxin Phase III trial in Haryana from November 20, Anil Vij will get the vaccine first

Posted on 18th Nov 2020 by rohit kumar

The practice of making Coronavirus vaccine in India is fast. The third phase trial of Bharat Biotech's Corona vaccine 'Kovaxine' in Haryana starts on November 20. Haryana Health Minister Anil Vij has offered to become the first volunteer to get the vaccine applied to him in a trial of cocaine. He has tweeted this information.

 

Haryana Health Minister Anil Vij tweeted, 'From November 20, the trial for the third phase of Bharat Biotech's coronavirus virus vaccine will start in Haryana. I have offered myself to be vaccinated as the first volunteer. '

 

Last month, Bharat Biotech said that it has completed the analysis of the first and second phase test data. Now after this, the company Bharat Biotech is going to start the third phase of human trials on 26,000 partners. It is being told that there will be a trial in different places of the country and this episode, there will be a third phase trial in Haryana as well.

 

Let us know that the pharmaceutical company Bharat Biotech is planning to introduce its vaccine (vaccine) for Covid-19 in the second quarter of next year. A top official of the company said that the company has this plan in case it gets the requisite clearances from the regulatory authorities of India. The company is currently focusing on Phase III trials at various locations in the country. The company has developed the potential vaccine Covaxin in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

 

Sai Prasad, executive director of Bharat Biotech International, said, 'If we get all the approvals after establishing strong experimental evidence and data, efficacy and safety data in our final phase of testing, then we will introduce it in the second quarter of 2021 Let's aim for He said that after obtaining approval from the Drugs Controller General of India (DCGI) to conduct Phase III clinical trials, preparation of sites for Phase III trials has been started.

Other news